Boston Scientific to Buy Vessix for Hypertension Device

Boston Scientific Corp., the second-largest seller of drug-coated stents, agreed to buy Vessix Vascular Inc. for as much as $425 million to speed its entry into the market for hard-to-treat hypertension devices.

Boston Scientific will pay $125 million for closely held Vessix, based in Laguna Hills, California, and as much as $300 million more by 2017 based on clinical and sales targets, the Natick, Massachusetts-based company said today in a statement. While the acquisition won’t affect earnings excluding one-time items through 2014, the costs and amortization related to the purchase may reduce net income, the company said.